Want to see TSE:OVAT full AI Analyst Report?
Top Page
Ovation Science
(OVAT)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.03
▲(0.00% Upside)
Action:Reiterated
Date:09/22/26
The score is held down primarily by very weak financial performance (persistent losses, negative cash generation, and negative equity signaling elevated financing/dilution risk). Technicals are moderately supportive with price above key moving averages, but mixed momentum limits upside. Valuation provides little support because losses make the negative P/E hard to interpret and there is no dividend yield data.
Positive Factors
Proprietary Transdermal Technology
A proprietary transdermal delivery approach can differentiate Ovation’s topical products from conventional formulations and provide a platform for multiple skin-related applications. If commercialization progresses, this technology-centered model may support repeat product development and longer-term competitive positioning.
Negative Factors
Persistent Unprofitability
Persistent operating and net losses show that the business has not yet established a profitable operating model. Continued losses can restrict reinvestment, weaken financial resilience, and make future growth dependent on outside capital unless revenue and margins improve sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Transdermal Technology
A proprietary transdermal delivery approach can differentiate Ovation’s topical products from conventional formulations and provide a platform for multiple skin-related applications. If commercialization progresses, this technology-centered model may support repeat product development and longer-term competitive positioning.
Read all positive factors
Ovation Science (OVAT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.15M
Dividend YieldN/A
Average Volume (3M)1.30K
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue Growth-11.38%
EPS Growth-35.88%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding38,441,680
10 Day Avg. Volume3,565
30 Day Avg. Volume1,305
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-0.98
Price to Sales (P/S)20.98
P/FCF Ratio-18.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ovation Science Business Overview & Revenue Model
Company Description
Ovation Science Inc. specializes in the creation of cannabis and hemp-based products, distributed across Canada, the United States, and Mexico. A cornerstone of its offerings is Invisicare, a patented drug delivery technology employed in topical a...
Ovation Science Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.34K | 67.89K | 113.22K | 61.93K | 138.15K | 224.95K |
| Gross Profit | -170.25K | -312.45K | 85.72K | -251.43K | 134.11K | -168.75K |
| EBITDA | -625.02K | -598.18K | -404.15K | -778.83K | -786.73K | -2.39M |
| Net Income | -655.91K | -631.25K | -456.20K | -813.15K | -794.05K | -2.39M |
Balance Sheet | ||||||
| Total Assets | 25.71K | 82.82K | 63.90K | 76.89K | 104.89K | 769.90K |
| Cash, Cash Equivalents and Short-Term Investments | 13.22K | 72.29K | 3.31K | 48.85K | 28.90K | 647.56K |
| Total Debt | 292.14K | 283.06K | 268.48K | 192.62K | 41.13K | 0.00 |
| Total Liabilities | 1.82M | 1.54M | 1.15M | 728.99K | 187.84K | 63.74K |
| Stockholders Equity | -1.79M | -1.46M | -1.09M | -652.10K | -82.95K | 706.15K |
Cash Flow | ||||||
| Free Cash Flow | -138.12K | -76.44K | -178.82K | -336.02K | -670.80K | -885.75K |
| Operating Cash Flow | -138.13K | -76.44K | -178.82K | -336.02K | -670.80K | -885.75K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M |
| Financing Cash Flow | 146.48K | 146.48K | 133.28K | 356.16K | 47.24K | 0.00 |
Ovation Science Technical Analysis
Positive
0.03
Price Trends
0.03
Positive
0.02
Positive
0.03
Positive
Market Momentum
<0.01
Negative
61.73
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OVAT, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.73 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OVAT.
Ovation Science Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | C$29.90M | -6.03 | -13.79% | ― | -6.74% | 43.54% | |
54 Neutral | C$58.21M | -2.27 | -25.01% | ― | 13.60% | 11.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$5.11M | -2.63 | -43.92% | ― | -18.30% | -397.37% | |
47 Neutral | C$1.15M | -1.69 | 41.93% | ― | -11.38% | -35.88% | |
47 Neutral | C$47.63M | -4.87 | 117.02% | ― | ― | ― | |
42 Neutral | C$58.28M | -0.76 | -2099.75% | ― | -100.00% | 94.43% |
* Healthcare Sector Average
TSE:OVAT
Ovation Science
0.03
>-0.01
-14.29%
TSE:ATLE
Willow Biosciences Inc
0.13
-0.05
-26.47%
TSE:LABS
MediPharm Labs
0.07
>-0.01
-6.67%
TSE:OILS
Nextleaf Solutions
0.03
-0.04
-57.14%
TSE:VEXT
Vext Science
0.24
-0.13
-35.62%
TSE:BNXT
BioNxt Solutions
0.35
-0.54
-60.67%
Ovation Science Corporate Events
Business Operations and StrategyExecutive/Board Changes
Ovation Science Mourns Death of Key Executive and Board Member
Negative
Sep 17, 2026
Ovation Science Inc. announced the death of board member and senior executive Doreen McMorran, who had served as Vice-President since 2017, Chief Operating Officer since 2018 and Chief Financial Officer since 2023. The company described McMorran a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.